

J. KAYNAKLAR

1. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. *Tubercle* 1991; 72:1-6.
2. Dye C, Scheele S, Dolin P, et al. Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country. *JAMA* 1999; 282:677-686.
3. World Health Organization. WHO Tuberculosis Programme: Framework for Effective Tuberculosis Control. 1994. WHO/TB/94.179.
4. Cantwell MF, Snider DE Jr, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. *JAMA* 1994; 272:535-539.
5. Zuber PLF, McKenna MT, Binkin NJ, et al. Long-term risk of tuberculosis among foreign-born persons in the United States. *JAMA* 1997; 278:304-307.
6. Davies PDO. Tuberculosis and migration. *Eur Respir Mon* 1997; 4:68-87.
7. WHO. Global Tuberculosis Control. Surveillance, Planning, Financing. Communicable Diseases, World Health Organization, Geneva: 2002. WHO/CDS/TB/2002.295.
8. WHO. Global DOTS Expansion Plan. Progress in TB control in high-burden countries, 2001. World Health Organization. WHO/CDS/STB/2001.11.
9. Stop tb: "www.stoptb.org"
10. Harvard Medical School / Open Society Institute. Review of tuberculosis control programs in Eastern and Central Europe and the Former Soviet Union. Boston, 2001.
11. Snider DE, Castro KG. The global threat of drug-resistant tuberculosis. *N Engl J Med* 1998; 338:1689-1690.
12. WHO/IUATLD. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 2000. WHO/CDS/TB/2000/278.
13. World Health Organization. Stop TB, Communicable Diseases. An Expanded DOTS Framework for Effective Tuberculosis Control. World Health Organization. Geneva, 2002. WHO/CDS/TB/2002.297.
14. EuroTB (InVS/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on tuberculosis cases notified in 1999, March 2002.
15. WHO. Global Tuberculosis Control. Communicable Diseases, World Health Organization, Geneva: 2000. WHO/CDS/TB/2000.275.
16. Bilgiç H. Tüberküloz Epidemiyolojisi. In: Kocabaş A. (Ed). Tüberküloz, Kliniği ve Kontrolü. Emel Matbaası, Ankara. 1991: 401-437.
17. Kuzuca İG, Canbakan SÖ, Mutlu AG, Küsmez AC. Ankara 2 Nolu Verem Savaş Dispanseri'nde 1996-1997 yıllarında izlenen 256 hastanın retrospektif olarak değerlendirilmesi. *Solunum Hastalıkları* 1999; 10:16-22.
18. Özkara Ş, Kılıçaslan Z, Öztürk F, et al. Bölge verileriyle Türkiye'de tüberküloz. *Toraks Dergisi* 2002; 3:178-187.
19. Behr MA, Warren SA, Salamon H, et al. Transmission of *Mycobacterium tuberculosis* from patients smear-negative for acid-fast bacilli. *Lancet* 1999; 353:444-449.
20. Valway SE, Sanchez MPC, Shinnick TF, et al. An outbreak of tuberculosis involving extensive transmission of a virulent strain of *M. tuberculosis*. *N Engl J Med* 1998; 338:633-639.

21. Duguid J. Expulsion of pathogenic organisms from the respiratory tract. Br Med J 1946; 1:245.
22. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-949.
23. Loudon RG, Romans WE. Cough frequency and infectivity in patients with pulmonary tuberculosis. Am Rev Respir Dis 1969; 99:109-111.
24. Small PM, Shafer RW, Hopewell PC. Exogenous reinfection with multidrug resistant *Mycobacterium tuberculosis* in patients with advanced HIV infection. N Engl J Med 1993; 328:1137-1144.
25. Templeton GL, Illing LA, Young L, et al. The risk of transmission of *Mycobacterium tuberculosis* at the bedside and during autopsy. Ann Intern Med 1995; 122:922-925.
26. Hutton MD, Stead WW, Cauthen GM, Bloch AB, Ewing WM, Nococonial transmission of tuberculosis associated with a draining abscess. J Infect Dis 1990; 161:286-295
27. Dannenberg AM. Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. Immunol Today 1991; 12:228-233.
28. Dannenberg AM. Pathophysiology: Basic Aspects. Ed: David Schlossberg: Tuberculosis and Nontuberculous Mycobacterial Infections. Fourth Edition. WB Saunders Company, Philadelphia, 1999.
29. Sutherland I. Recent studies in the epidemiology of tuberculosis based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976; 19:1-63.
30. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel studies. Am Rev Respir Dis 1979; 119:827-830.
31. Horwitz O. The risk of tuberculosis in different groups of the general population. Scand J Respir Dis 1970; 72 (suppl):55-60.
32. Cowie RL. The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med 1994; 150:1460-1462.
33. Westerholm P, Ahlmark A, Maasing R, Segelberg I. Silicosis and risk of lung cancer or lung tuberculosis: a cohort study. Environ Res 1986; 41: 339-350.
34. Alcaide J, Altet MN, Plans P, et al. Cigarette smoking as a risk factor for tuberculosis in young adults: a case-control study. Tuberc Lung Dis 1996; 77:112-116.
35. Altet MN, Alcaide J, Plans P, et al. Passive smoking and risk of pulmonary tuberculosis in children immediately following infection. A case-control study. Tuberc Lung Dis 1996; 77:537-544.
36. IUAT Committee on Prophylaxis. The efficacy of varying durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO 1965; 60:555-564.
37. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970; 17:28-106.
38. Palmer CE, Jablon S, Edwards PQ. Tuberculosis morbidity of young men in relation to tuberculin sensitivity and body build. Am Rev Tuberc 1957; 76:517-539.
39. A Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161(4 Pt 2):S221-247.
40. Toman K. Tuberculosis, case-finding and chemotherapy. Questions and Answers. World Health Organization, Geneva. 1979:122-129.

41. WHO Technical Report Series, No 552, 1974. (Ninth report of the WHO Expert Committee on Tuberculosis).
42. Clarridge JE, Shawar RM, Shinnick TM, et al. Large-scale use of polymerase chain reaction for detection of *Mycobacterium tuberculosis* in a routine mycobacteriology laboratory. J Clin Microbiol 1993; 31:2049-2056.
43. Long R (ed). Canadian Tuberculosis Standards. 5th Edition. Canadian Lung Association 2000.
44. Iseman MD. Klinisyenler için Tüberküloz Kılavuzu. (Erişkinlerde Akciğer Dışı Tüberküloz) Çeviren: Ş. Özkara. Nobel Tıp Kitabevleri, İstanbul. 2002: s.145-197.
45. Schlossberg D (editör). Tüberküloz. 3. Baskı. Çeviri Editörü: Tetikkurt C. Bilimsel ve Teknik Yayınları Çeviri Vakfı, İstanbul, 1995:81-197.
46. Schlossberg D, Zorab R (Ed's). Tuberculosis and Nontuberculous Mycobacterial Infections. W B Saunders; Philadelphia. 4th edition, 1999.
47. Sağlık Bakanlığı Verem Savaşı Daire Başkanlığı. Tüberküloz hastalarının tanı-tedavi ve izlenmesi. Sağlık Projesi Genel Koordinatörlüğü ve Verem Savaşı Daire Başkanlığı Yayını, Ankara, 1998.
48. Maher D, Chaulet P, Spinaci S, Harries A. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes: Second Edition, Geneva: 1997.
48. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes Geneva, World Health Organization. 1997. WHO/TB/97.220.
49. Migliori GB, Raviglione MC, Schaberg T, et al. Task Force of ERS, WHO and the Europe Region of IUATLD. Tuberculosis management in Europe. Eur Respir J 1999; 14:979-992.
50. Enarson DA, Rieder HL, Arnadottir T, Trebuçq A. Management of tuberculosis, A guide for low income countries. 5th edition, 2000, International Union Against Tuberculosis and Lung Disease.
51. Gryzbowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis Bull IUAT 1975; 50:90-106.
52. Capewell S, Leitch AG. The value of contact procedures for tuberculosis in Edinburgh. Br J Dis Chest 1984; 78:317-328.
53. Clancy L, Rieder HL, Enarson DA, Spinaci S. Tuberculosis elimination in the countries of Europe and other industrialized countries. Eur Respir J 1991; 4:1283-1295.
54. Küçük G, Kümbetli Ş, Sarımurat N, et al. Yayma (+) akciğer tüberkülozlu olguların 15 yaş üzeri temaslılarında takip sonuçları. Toraks Dergisi 2002; 3(ek1):1 (özet).
55. Kiter G, Arpaz S, Keskin S, et al. Tuberculosis in Nazilli District Prison, Turkey, 1997-2001. Int J Tuberc Lung Dis 2003; 7:153-158.
56. Özkara Ş. Sağlık kurumlarında tüberküloz bulaşması ve alınması gereken önlemler. Toraks Dergisi 2002; 3:89-97.
57. Fox W, Mitchison DA. Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1975; 111:325-353.
58. Iseman MD. Klinisyenler İçin Tüberküloz Kılavuzu. Çeviren: Ş. Özkara. Nobel Tıp Kitabevleri, İstanbul. 2002; s.291.
59. Mitchison D. Mechanisms of the action of drugs in the short-course chemotherapy. Bull Int Union Tuberc 1985; 60:36-40.
60. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66:219-225.

61. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes Geneva, World Health Organization. 1997. WHO/TB/97.220, s. 34.
62. Sevim T, Ataç G, Güngör G, et al. Treatment outcome of relapse and defaulter pulmonary tuberculosis patients. *Int J Tuberc Lung Dis* 2002; 6:320-325.
63. Sbarbaro J, Blomberg B, Chaulet P. Fixed-dose combination formulations for tuberculosis treatment. *Int J Tuberc Lung Dis* 1999; 3 (suppl 3): S286-S288 (Ayrıca bu dergi ekinin konusu şudur: "Quality assurance of fixed-dose combinations of anti-tuberculosis medications").
64. Alzeer AH, FitzGerald JM. Corticosteroids and tuberculosis: risks and use as adjunct therapy. *Tuberc Lung Dis* 1993; 74:6-11.
65. Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. *Clin Infect Dis* 1997; 25:872-887.
66. Wyser C, Walzl G, Smedema JP, Swart F, et al. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo controlled, randomized study. *Chest* 1996; 110:333-338.
67. Lee CH, Wang WJ, Lan RS, Tsai YH, Chiang YC. Corticosteroids in the treatment of tuberculous pleurisy. *Chest* 1988; 94:1256-1259.
68. Strang JIF, Kakaza HHS, Gibson DG, et al. Controlled trial of prednisone as adjunct in treatment of tuberculosis constrictive pericarditis in Trankei. *Lancet* 1987; 2:1418-1422.
69. Girgis NI, Farid Z, Kilpatrick ME, et al. Dexamethasone as an adjunct to treatment of tuberculosis meningitis. *Ped Infect Dis J* 1991; 10:179-183.
70. Schoeman JF, Van Zyl LE, Laubscher JA, et al. Effect of corticosteroids on intracranial pressure, computed tomographic finding, and clinical outcome in young children with tuberculous meningitis. *Pediatrics* 1997; 99:226-231.
71. Nemir RL, Cardona J, Vaziri F, Toledo R. Prednisone as an adjunct in the chemotherapy of lymph node-bronchial tuberculosis in childhood: a double-blind study, II: further term observation. *Am Rev Respir Dis* 1967; 95: 402-410.
72. Smith MHD, Matsamotis N. Treatment of tuberculous pleural effusions with particular reference to adrenal corticosteroids. *Pediatrics* 1958; 22:1074-1087.
73. Kır A. Tüberküloz Cerrahisi. Yüksel M, Kalaycı NG. (editörler): Göğüs Cerrahisi. Bimedya Grup, İstanbul; 2001: 789-797.
74. Girling DJ. Adverse effects of antituberculosis drugs. *Drugs* 1982; 23:56-74.
75. Snider DE Jr. Pyridoxine supplementation during isoniazid therapy. *Tubercle* 1980; 61:191-196.
76. Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City: turning the tide. *N Engl J Med* 1995; 333:229-233.
77. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. *Lancet* 1996; 347:358-362.
78. WHO. Stop TB at the Source. WHO Report on the Tuberculosis Epidemic, 1995. World Health Organization, Geneva. WHO/TB/95.183.
79. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. *JAMA* 1995; 274:945-951.
80. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. *N Engl J Med* 1994; 330:1179-1184.

81. Enarson D. Principles of IUATLD Collaborative Tuberculosis Programme. Bull Int Union Tuber Lung Dis 1991; 66:195-200.
82. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis. JAMA 1998; 279:943-948.
83. Pablos-Mendez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276:1223-1228.
84. Chen X, Zhao F, Duanmu H, et al. The DOTS strategy in China: results and lessons after 10 years. Bull WHO 2002; 80:430-436.
85. Moore RD, Chaulk CP, Griffiths R, et al. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996; 154:1013-1019.
86. Burman WJ, Dalton CB, Cohn DL, et al. A cost-effectiveness analysis of directly observed therapy vs. self-administered therapy for treatment of tuberculosis. Chest 1997; 112:63-70.
87. Arpaz S, Keskin S, Sezgin N, ve ark. Nazilli Verem Savaş Dispanseri DOTS Deneyimi Sonuçları. Toraks Dergisi 2001; 2 (ek 1): 40 (özet).
88. Arpaz S, Budin D, Keskin S, ve ark. Doğrudan gözetimli tedavi ile tedavi edilen 104 tüberküloz olgusunun sonuçları. Toraks Dergisi 2002; 3 (ek 1): 1 (özet).
89. Talu A, Abdüloğlu B, Bilgiç B, ve ark. Denizli Verem Savaş Dispanseri’nde direkt gözetim tedavisi uygulaması. Toraks Dergisi 2002; 3 (ek 1): 2 (özet).
90. Aydın M, Dalan H, Akyüz S, Amasya H. Aydın Dernek Verem Savaşı Dispanseri’nin doğrudan gözetimli tedavi uygulaması. Toraks Dergisi 2002; 3 (ek 1): 71 (özet).
91. Burman WJ, Cohn DL, Rietmeijer CA, et. al. Short-term incarceration for the management of noncompliance with tuberculosis treatment. Chest 1997; 112:57-62.
92. Oscherwitz T, Tulsy P, Roger S, et al. Detention of persistently nonadherent patients with tuberculosis. JAMA 1997; 278:843-846.
93. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-662.
94. Malone RS, Fish DN, Spiegel DM, et al. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med 1999; 159:1580-1584.
95. Hong Kong Chest Service/Tuberculosis Research Centre/British Medical Research Council. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis 1991; 143: 262-267.
96. Lin TP, Suo J, Lee CN, Lee JJ, Yang SP. Short-course chemotherapy of pulmonary tuberculosis in pneumoconiotic patients. Am Rev Respir Dis 1987; 136:808-810.
97. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-1374.
98. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 (Suppl 2):S231-S279.
99. British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53:536-548.
100. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360:528-534.

101. WHO. Managing TB at district level. World Health Organization, Geneva: 1996.
102. Al-Moamary MS, Black W, Bessuille E, et al.. The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis. Chest 1999; 116: 726-731.
103. Vidal R, Martin-Casabona N, Juan A, et al. Incidence and significance of acid-fast bacilli in sputum smears at the end of antituberculous treatment. Chest 1996; 109:1562-1565.
104. Kim TC, Blackman RS, Heatwole KM, et al. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Prevalence and significance of negative smears pretreatment and positive smears post-treatment. Am Rev Respir Dis 1984; 129: 264-268.
105. Farmer PE, Bayona J, Becerra M, et al. The dilemma of MDRTB in the global era. Int J Tuberc Lung Dis 1998; 2:869-876.
106. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2:10-15.
107. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133:423-430.
108. Fox W. The chemotherapy of pulmonary tuberculosis: a review. Chest 1979; 76(suppl):785-796.
109. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119:579-585.
110. Centers for Disease Control and Prevention. Core Curriculum on Tuberculosis, What the Clinician Should Know, Fourth Edition, 2000, Atlanta, Georgia.
111. Zierski M, Bek E, Long MW, Snider DE Jr. Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment. Am Rev Respir Dis 1981; 124:249-251.
112. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136:1339-1342.
113. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283:2537-2545.
114. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 328: 784-791.
115. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345:170-174.
116. Iseman MD. Klinisyenler için Tüberküloz Kılavuzu. Çeviren: Ş. Özkara. [İnsan immünyetmezlik Virüsü (HIV) ve Edinsel İmmünyetmezlik Sendromu (AIDS) ile İlişkili Tüberküloz]. Nobel Tıp Kitabevleri, İstanbul. 2002: s.199-252.
117. WHO. TB/HIV. A Clinical Manual. World Health Organization, Geneva: 1996.
118. Medical Research Council. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Bull WHO 1972; 46:371-385.
119. Khan EA, Starke JR. Diagnosis of tuberculosis in children: increased need for better methods. Emerging Infect Dis 1995; 4:115-123.
120. American Academy of Pediatrics Committee on Infectious Diseases. Screening for tuberculosis in infants and children. Pediatrics 1994; 93:131-134.
121. Stegner P, Rao M, Victoria MS, et al. Persistently negative tuberculin reactions: their presence among children culture positive for *M. tuberculosis*. Am J Dis Child 1980; 134: 747-750.

122. Starke JR, Taylor-Watts KT. Tuberculosis in the pediatric population of Houston, Texas. *Pediatrics* 1989; 84:28-35.
123. Iseman MD. Klinisyenler için Tüberküloz Kılavuzu. (Pediatrik Tüberküloz). Çeviren: Ş. Özkara: Nobel Tıp Kitabevleri, İstanbul. 2002:253-269.
124. Leung AN, Muller NL, Pineda PR, et al. Primary tuberculosis in childhood: radiographic manifestations. *Radiology* 1992; 182:87-91.
125. Ngu N, Saiman L, San Gabriel P, et al. Diagnosis of pediatric tuberculosis in the modern era. *Pediatr Inf Dis J* 1999; 18:122-126.
126. Shata AMA, Carter JBS, Parry CM, et al. Sputum induction for the diagnosis of tuberculosis. *Arch Dis Child* 1996;74: 535-537.
127. Trebecq A. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. *Int J Tuberc Lung Dis* 1997; 1:12-15.
128. Sbarbaro JA. Skin test antigens: an evaluation whose time has come. *Am Rev Respir Dis* 1978; 118:1-5.
129. Zack MB, Fulkerson LL. Clinical reliability of stabilized and nonstabilized tuberculin PPD. *Am Rev Respir Dis* 1970; 102:91-93.
130. Holden M, Dubin MR, Diamond PH. Frequency of negative intermediate-strength tuberculin sensitivity in patients with active tuberculosis. *N Engl J Med* 1971; 285:1506-1509.
131. Iseman MD. Klinisyenler İçin Tüberküloz Kılavuzu. (Tüberkülozun koruyucu tedavisi). Çeviren: Ş. Özkara. Nobel Tıp Kitabevleri, İstanbul. 2002; s.199-252.
132. Özkara Ş, Aktaş Z, Özkan S, Ecevit H. Verem Savaşı Daire Başkanlığı: Türkiye'de tüberkülozun kontrolü için kılavuz (tartışma için taslak), Ankara: 1999.
133. Iseman MD. Klinisyenler İçin Tüberküloz Kılavuzu. Çeviren: Ş. Özkara. Nobel Tıp Kitabevleri, İstanbul. 2002; s.390.
134. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR, ed. *Tuberculosis: Pathogenesis, Protection and Control*. Washington DC, American Society for Microbiology Press, 1994; pp. 531-557.
135. Sutherland I, Lindgren I. The protective effect of BCG vaccination as indicated by autopsy studies. *Tubercle* 1979; 60:225-231.
136. Gocmen A, Kiper N, Ertan U, et al. Is the BCG test of diagnostic value in tuberculosis? *Tuber Lung Dis* 1994; 75:54-57.
137. Koçoğlu F. Tüberküloz Sorununun Çözümünde Günümüzde Uygulanan Kontrol Yöntemlerinin Etkinliği. In: Kocabaş A. (Ed). *Tüberküloz, Kliniği ve Kontrolü*. Emel Matbaası, Ankara. 1991: 439-443.
138. Riley R, Nardell E. Cleaning the air: the theory and application of ultraviolet air disinfection. *Am Rev Respir Dis* 1989; 139:1286-1294.
139. Fennelly KP. Personal respiratory protection against *Mycobacterium tuberculosis*. Iseman MD, Huitt GA (editors). *Clinics in Chest Med*. Philadelphia: WB Saunders, 1996:1-17.
140. Dunlap NE, Bass J, Fujiwara P, et al. American Thoracic Society and the Centers For Disease Control and Prevention. Diagnostic standarts and classification of tuberculosis in adults and children. *Am J Respir Crit Care Med* 2000; 161:1376-1395.
141. Heifets LB (ed). *Clinical mycobacteriology*. Clinics in laboratory medicine. WB Saunders Co., Philedelphia PA. 1996.
142. Gümüslü F, Ceyhan İ, Kocagöz T, Sönmez N. Tüberküloz Laboratuvar Rehberi. TC Sağlık Bakanlığı, Refik Saydam Hfzıssıhha Merkezi Başkanlığı. Ankara, 1988.